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The adipokine leptin modulates 
adventitial pericyte functions by 
autocrine and paracrine signalling
Federica Riu1,2, Sadie C. Slater  1, Eva Jover Garcia1, Iker Rodriguez-Arabaolaza1, Valeria 
Alvino1, Elisa Avolio1, Giuseppe Mangialardi1, Andrea Cordaro1, Simon Satchell1, Carlo 
Zebele1, Andrea Caporali3, Gianni Angelini1 & Paolo Madeddu1
Transplantation of adventitial pericytes (APCs) improves recovery from tissue ischemia in preclinical 
animal models by still unknown mechanisms. This study investigates the role of the adipokine leptin 
(LEP) in the regulation of human APC biological functions. Transcriptomic analysis of APCs showed 
components of the LEP signalling pathway are modulated by hypoxia. Kinetic studies indicate cultured 
APCs release high amounts of immunoreactive LEP following exposure to hypoxia, continuing upon 
return to normoxia. Secreted LEP activates an autocrine/paracrine loop through binding to the LEP 
receptor (LEPR) and induction of STAT3 phosphorylation. Titration studies using recombinant LEP 
and siRNA knockdown of LEP or LEPR demonstrate the adipokine exerts important regulatory roles 
in APC growth, survival, migration and promotion of endothelial network formation. Heterogeneity 
in LEP expression and secretion may influence the reparative proficiency of APC therapy. Accordingly, 
the levels of LEP secretion predict the microvascular outcome of APCs transplantation in a mouse limb 
ischemia model. Moreover, we found that the expression of the Lepr gene is upregulated on resident 
vascular cells from murine ischemic muscles, thus providing a permissive milieu to transplanted LEP-
expressing APCs. Results highlight a new mechanism responsible for APC adaptation to hypoxia and 
instrumental to vascular repair.
Multipotent mesenchymal cells from the vascular wall, alias adventitial pericytes (APCs), are emerging as prom-
ising candidates for therapeutic vasculogenesis1–4. Evidence from our group and others indicate that trans-
plantation of human APCs promotes vascular and muscular repair in models of peripheral and myocardial 
ischemia5–9. Transplanted APCs incorporate into the host’s vasculature and release angiocrine factors, including 
Angiopoietin-1, VEGF-A and microRNA-132. The angiocrine activity of APCs is enhanced by hypoxia, thus 
accounting for their advantaged proangiogenic action upon transplantation into an ischemic tissue9, 10. However, 
paracrine mechanisms activated by hypoxia are still incompletely understood.
Leptin (LEP) is a hypoxia-inducible adipocytokine that plays a key role in the central regulation of food intake 
and energy expenditure11–13, and also participates in the modulation of immunity14, bone formation15, and cardi-
ovascular function16. Seminal evidence indicates components of the LEP pathway are expressed in human stem 
cells, but the pathophysiological implications of the LEP signalling remain unclear and controversial. The LEP 
receptor (LEPR) is highly expressed by embryonic stem cells and induced pluripotent stem cells, suggesting that 
LEP regulates relevant functions in these primitive cells17. In the adult bone marrow (BM), the LEPR identifies 
medullary mesenchymal stem cells (MSCs)18 as well as pericyte-like stromal cells that support hematopoiesis 
within the vascular niche19–21. Upregulation of the LEPR gene in cultured BM-MSCs has been associated with ces-
sation of growth due to replicative senescence22. Two recent studies showed that hypoxia-preconditioned murine 
BM-MSCs exert enhanced regenerative actions through an amplification of the LEP signalling23, 24. Nevertheless, 
the functional relevance of the LEP pathway in human pericytes remains unknown.
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The present study investigates the expressional regulation and functional actions of LEP in human APCs. 
We show for the first time that APCs secrete abundant levels of LEP under hypoxia, by one order of magnitude 
higher than BM-MSCs. APC-derived LEP exerts autocrine promotion of APCs survival and migration as well as 
paracrine stimulation of endothelial cell (EC) proliferation, permeability, and network formation. Importantly, 
the levels of secreted LEP predict the angiogenic activity of APC transplantation in a murine model of peripheral 
ischemia. Moreover, the expression of the Lepr gene is upregulated on vascular cells from mouse ischemic mus-
cles, thus increasing resident cells sensitivity to the restorative action of LEP-releasing APCs. Altogether, these 
results revealing a novel signalling mechanism instrumental to APC functionalities may have a far-reaching and 
critical impact on cardiovascular regenerative medicine.
Results
Effect of hypoxia on global gene expression in human APCs. Saphenous vein leftovers were obtained 
from 24 patients undergoing coronary artery bypass graft surgery. We succeeded in isolating and expanding 
21 APC lines (88% of processed veins), using a standard protocol described in the methods section and previ-
ous publications5, 6. Clinical and demographic characteristics of the corresponding 21 patients are provided in 
Supplementary Table I. The phenotype of human APCs have been extensively characterized2, 5, 6, 9. In four biologi-
cal replicates, here we demonstrate APCs have similar morphology when cultured under normoxia or hypoxia, as 
assessed by contrast phase microscopy (Supplementary Figure Ia). Likewise, hypoxia does not alter the expression 
of surface markers, as identified by flow cytometry and immunocytochemistry (Supplementary Figure Ib–e and 
Supplementary Table II).
Results from an Agilent human gene microarray on four individual APC lines, selected at random from the 
collective of 21 cell lines, indicate that 410 out of 2050 expressed genes are modulated by hypoxia, with a log2 fold 
change >1 and a p-value < 0.05. Here, in the interest of conciseness and clarity, we report the list of the top 131 
genes that exhibited a highly-significant (p < 0.01) upregulation (n = 72) or downregulation (n = 59) following 
hypoxia Supplementary Table III. In particular, LEP was found to be strongly upregulated by hypoxia (log2 fold 
change: 1.83, p = 0.006) together with several members of the LEP signalling pathway (Fig. 1). Statistical analysis 
using the String software available at http://string-db.org/ indicates a biologically relevant interaction among the 
studied genes (enrichment p-value = 1.11e-16). In addition, using the Ingenuity Pathway Analysis (IPA) software, 
we found that LEP is associated with all the main biofunctions/pathways found to be significantly modulated by 
hypoxia, including the regulation of cell death and survival, development, energy production and tissue mor-
phology (Supplementary Figure II). Next, by screening the networks encompassing the highest number of genes 
regulated in the dataset (Supplementary Table IV), we found that LEP is modulated together with other 18 genes 
in a network of 29 genes, whose function is associated with cell death/apoptosis and cell-to-cell signalling/inter-
action (Supplementary Table V). To the best of our knowledge, this is the first report on the global gene signature 
induced by low oxygen in human APCs.
Human APCs produce and release remarkable amounts of LEP under hypoxia. We next assessed 
the capacity of human APCs to secrete LEP. Measurement of LEP protein levels in conditioned media by ELISA 
showed a marked increase following 48 h exposure to hypoxia (Fig. 2a, n = 21, p < 0.001 vs. normoxia). A refer-
ence analysis of the secretory ability of BM-MSCs, collected from patients undergoing hip replacement surgery 
(see methods for details), showed no significant change in LEP levels following hypoxia (Fig. 2b, n = 3, p = 0.09 
Figure 1. Hypoxia modulates the LEP signalling pathway in human APCs. Transcriptional network 
generated by the String software on data derived from the Agilent array. (a) Legend of the impacted genes, (b) 
graphical illustration of the interconnected genes, and (c) legend of the type and effect of actions illustrated by 
interconnecting lines.
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Figure 2. Hypoxia induces leptin production and secretion by human APCs. (a) Highly induced LEP protein 
levels in APC conditioned media collected under hypoxia as compared with normoxia. Data are medians and 
5–95 percentiles from twenty-one APCs lines. ***p < 0.01. (b) LEP protein levels in conditioned media of BM-
MNCs (n = 3, p = 0.09 vs. normoxia). (c) Time course of LEP transcription and LEP protein production and 
secretion under hypoxia and following return to normoxia in three individual APC lines. Data are mean and 
SEM. (d) Concomitant changes in LEPR mRNA levels in the same cell lines. (e) Representative immunoblots 
for the expression of LEPR protein in APCs under normoxia and hypoxia during 48 h. Band densitometry 
was determined using Image J software and the fold change was calculated per each APC line (n = 3). Data are 
shown as mean ± SEM and asterisk means statistical significance as per p = 0.049.
www.nature.com/scientificreports/
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vs. normoxia). No association was found when comparing LEP secretion and subjects’ age, body mass index, 
smoking habit and grading of angina pectoris.
To gain an accurate insight into the kinetics of the LEP signalling induction, we studied the time course of 
LEP and LEPR transcription and LEP intracellular content and secretion in three individual APCs lines. Results 
show LEP mRNA levels peak between 12 and 24 h of hypoxia, with 24 h post-hypoxic normoxia being sufficient 
for restoration of the basal expressional state. In contrast, intracellular and secreted LEP protein levels remained 
elevated even after normoxia restoration (Fig. 2c). The expression of LEPR was variable but not significantly 
changed during exposure to hypoxia and return to normoxia (Fig. 2d). LEPR protein, assessed by Western blot, 
was upregulated by 1.29 ± 0.01 fold change (p < 0.05) in APCs exposed to hypoxia for 48 h (Fig. 2e), the time 
point chosen in our previous experiments.
It is known that LEP is transcriptionally regulated by the Hypoxia-Inducible Factor 1-alpha (HIF1α) through 
binding of the transcription factor to the hypoxia response element (HRE) promoter site of the LEP gene.
In addition, a recent investigation showed that forced miR-210 expression remarkably increases LEP secre-
tion in murine HL-1 cardiomyocytes25. Also, in hypothalamic neurons and NIH/3T3 reporter cells, miR-210 
enhances LEP signalling by inhibiting the protein-tyrosine phosphatase PTP1B, which acts as a negative regula-
tor through the dephosphorylation of the LEPR-associated Janus kinase 2 (JAK2)25, 26. Among the differentially 
expressed microRNAs, the Agilent array identified miR-210 to be strongly upregulated in human APCs exposed 
to hypoxia. This data was confirmed by qPCR analysis, showing a 14-fold increase in miR-210 levels after 48 h 
exposure to hypoxia (Supplementary Figure IIIa). We next inhibited miR-210 in four human APC lines using 
a specific antago-miR. Effective inhibition of miR-210 was confirmed by qPCR, either in normoxia or hypoxia 
(Supplementary Figure IIIa). However, the LEP gene and intracellular or secreted LEP protein expression were 
not affected by the miR-210 inhibition (Supplementary Figure IIIb–d). When considering PTP1B, we found no 
change under hypoxia vs. normoxia (Supplementary Figure IIIe), and observed a modest but significant upregula-
tion following miR-210 inhibition in hypoxic APCs (p < 0.05 vs. scramble, Supplementary Figure IIIf). However, 
this effect was associated with no change in the phosphorylation levels of JAK2 (Supplementary Figure IIIg). 
Altogether, these data militate against a role of hypoximiR-210 in the modulation of the LEP signalling, which is 
at variance with the results of previous studies in other cell types25, 26.
Human APCs are functionally responsive to exogenous LEP stimulation. We next assessed 
the responses evoked by recombinant human LEP (rhLEP) on human APCs under normoxic conditions. The 
molecular analysis focused on STAT3 and AKT, which are canonical mediators of LEP intracellular signalling. 
In four APCs lines tested, rhLEP significantly increased the phosphorylation of STAT3 (Tyr105) while reducing 
AKT phosphorylation (p < 0.05 for both comparisons, Fig. 3a). Moreover, we explored the functional effects of 
increasing doses of rhLEP up to the upregulated endogenous levels seen under hypoxia. Interestingly, exposure of 
APCs to rhLEP reduces proliferation (assessed by BrdU incorporation, Fig. 3b) and exerts anti-apoptotic actions 
(assessed by caspase 3/7) (Fig. 3c). The anti-proliferative response was dose-related while the anti-apoptotic effect 
reached a plateau already at the lowest rhLEP dosage. These data highlight the functional competence of the LEP 
signalling machinery in human APCs.
Autocrine action of endogenous LEP in human APCs. Having demonstrated that human APCs are 
responsive to an artificial increase in the environmental levels of LEP, we next investigated the functional rele-
vance of the autocrine LEP signalling stimulated by hypoxia. First, we confirmed that hypoxia induces the phos-
phorylation of STAT3 in human APCs. There was no significant change in pERK and pAKT levels before and after 
hypoxia (Fig. 4a). We then silenced LEP or LEPR by siRNA in four hypoxic APC lines, using scramble sequences 
as a control. The effective knockdown was confirmed at mRNA and protein level (Supplementary Figure IVa–c). 
Importantly, LEP silencing reduced STAT3 and ERK phosphorylation in hypoxic APCs (Fig. 4b). Silencing of 
the LEPR reproduced the same effect in hypoxic APCs (Fig. 4c). STAT3 and ERK are canonical downstream 
modulators of LEP biological actions; therefore, their reduction after LEP or LEPR silencing confirm that hypoxia 
activates a canonical kinase signalling in APCs. Next, we explored the effect of LEP inhibition on hypoxic APCs. 
Results indicate that knockdown of LEP results in increased cell proliferation (Fig. 4d) and apoptosis (Fig. 4e and 
f). Similar results were observed following silencing of the LEPR (Fig. 4d–f), thus suggesting an autocrine loop 
of secreted LEP. Moreover, LEP silencing significantly decreased the migration of hypoxic APCs in an in vitro 
scratch assay, however silencing of the LEPR produced no significant effect on migration (Fig. 4g).
Secreted LEP contributes to APC-induced promotion of angiogenesis. Previous studies have 
shown that APCs interact with ECs to stimulate angiogenesis5, 6, 9, but it is not known if LEP contributes to this 
action. Hence, we next investigated the effect of APC-derived LEP on EC functions, including proliferation, 
network formation, and permeability. To this aim, LEPR-silenced or scramble-treated HUVECs were exposed 
to conditioned media collected from normoxic or hypoxic APCs. As expected, siRNA silencing significantly 
reduced the expression of the LEPR in HUVECs (Supplementary Figure IVd), which made them less responsive 
to the stimulatory action of hypoxic APC-CM on proliferation (Fig. 5a) and network formation (Fig. 5b). Initial 
stages of angiogenesis are associated with the loss of mutual contacts between ECs, resulting in increased perme-
ability of the endothelial layer. We found silencing LEP in APCs or LEPR in HUVECs results in decreased ability 
of hypoxic APC conditioned media to induce endothelial permeability as assessed by evaluating HUVEC mon-
olayer electrical resistance (Fig. 5c). Altogether, these data indicate that secreted LEP contributes to the functional 
cross-talk between APCs and ECs.
LEP expression predicts the angiogenic effect of APC transplantation in a model of peripheral 
ischemia. Having demonstrated that APC-produced LEP promotes autocrine and angiocrine effects in vitro, 
www.nature.com/scientificreports/
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we next investigated if the adipokine helps to predict the outcomes of APC therapy in a mouse model of limb 
ischemia. In line with the recommended use of historical data to reduce animal numbers (The National Centre 
for the Replacement Refinement & Reduction of Animals in Research, https://www.nc3rs.org.uk), we conducted 
a retrospective analysis of a published study from our laboratory10. The study consisted of in vitro functional 
and biochemical assays on five APC lines (including measurement of LEP levels in conditioned media collected 
under hypoxia) and in vivo experiments on inbred C57BL/6 mice, which were randomly assigned to vehicle or 
APC therapy (n = 7 per group). All mice completed the assessment of outcomes, i.e. blood flow recovery of the 
ischemic limb (laser Doppler) and muscular capillary density (immunohistochemistry), at the end of the 28 days 
follow up. Both in vivo outcomes and LEP measurements in APC conditioned media were assessed by investiga-
tors blind to the treatment randomization protocol.
APCs transplantation improved the hemodynamic outcome (time-weighted blood flow recovery: 0.48 ± 0.02 
Doppler units [min 0.38 ± 0.04, max 0.61 ± 0.08] vs. 0.32 ± 0.05 Doppler units in the vehicle-injected group, 
p < 0.01) and also increased capillary density in the ischemic muscle (813 ± 39 cap/mm2 [min 727 ± 80, max 
947 ± 112] vs, 660 ± 12 cap/mm2 in the vehicle-injected group, p < 0.01). No association was found between the 
Doppler blood flow data and the capillary density in ischemic muscles. Hence, these parameters were considered 
as separate outcome indexes in the retrospective analysis of LEP as a predictor of therapeutic efficacy. We did 
not find any association between LEP levels in the conditioned media of injected APCs and perfusion recovery 
(R2 = 0.35, p = N.S.). On the other hand, there was an association between LEP levels in APC conditioned media 
and capillary density in the ischemic muscles (R2 = 0.72, p < 0.05, Fig. 6a and b). In contrast, the levels of VEGF-A 
and Angiopoietin-1 did not correlate with muscle capillarization (data not shown). Thus, the assessment of LEP 
helps to predict the microvascular outcome of APC therapy in a mouse model of limb ischemia. Furthermore, 
qPCR analysis of NG2 + pericytes and CD31 + ECs cells extracted from limb muscles of mice 3 days after induc-
tion of ischemia showed a significant increase in the expression of the murine Lepr in both cell types when com-
pared with cells extracted from contralateral normoperfused muscles (n = 5 per group, p < 0.001, Fig. 6c and d).
Figure 3. Effect of exogenous recombinant leptin on canonical signalling and functional assays in human 
APCs. (a) Representative immunoblots of phosphorylated and total proteins. Bar graphs show the average of 
four biological replicates. Cells were stimulated with 1 ng/mL rh-LEP. *p < 0.05 vs. vehicle. (b) Proliferation 
assay of four APC lines performed following stimulation with increasing doses of rh-LEP under normoxia. 
*p < 0.05 and **p < 0.01 vs. vehicle. (c) Apoptosis assay performed under normoxia. *p < 0.05, **p < 0.01 and 
***p < 0.001 vs. vehicle. Values are mean and SEM.
www.nature.com/scientificreports/
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Discussion
This study newly shows LEP and its receptor are key players in the functional adaptation of human APCs to a 
hypoxic environment. Induction of LEP expression by hypoxia inhibits APCs proliferation and apoptosis while 
augmenting the APCs migratory ability and proangiogenic activity.
Figure 4. Effect of LEP silencing. Expression and phosphorylation levels of leptin-associated kinases in 
normoxic and hypoxic APCs (a), and effect of LEP (b) or LEPR (c) silencing on kinase phosphorylation in 
hypoxic APCs. Representative immunoblots of phosphorylated and total proteins are displayed. Bar graphs 
show the average of four biological replicates. *p < 0.05 vs. normoxia. (d–f) Silencing of LEP and its receptor 
in hypoxic APCs induces cell proliferation (d) and also exerts pro-apoptotic effects as assessed by the caspase 
activity assay (e) and the expression of BCL-2 and BAX (f). **p < 0.01 and ***p < 0.001 vs. scramble. (g) LEP 
silencing reduces the migratory activity of APCs in a scratch assay performed under hypoxia, however LEPR 
silencing was unable to induce significant changes in APC migration. Representative contrast microscopy 
images and bar graph showing average data. *p < 0.05 vs. scramble.
www.nature.com/scientificreports/
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Previous reports have shown that hypoxia-preconditioned murine MSCs exert cardio-protective effects in 
preclinical models through a paracrine mechanism involving the murine Lep23, 24. However, the modulation and 
regulatory roles of LEP in human pericytes has not been investigated so far. Hence, this is the first documentation 
of LEP being essential for the functional responses of human APCs to hypoxia. LEP is promptly transcribed upon 
APCs exposure to low oxygen and accumulates in the intracellular compartment, thereby allowing prolonged 
secretion after cell return to normoxia. The APCs capacity to secrete LEP under hypoxia is exceptional, consid-
ering protein levels in the APC-CM are ~10 times higher compared with those reported in the present study and 
in a previous publications in BM-MSCs23. Also, functional analysis of gene arrays indicates that hypoxia triggers 
a network of proangiogenic and prosurvival genes, which may cooperate with LEP in influencing a spectrum of 
autocrine and paracrine functions.
The best-characterized molecular mechanism downstream of LEP involves the JAK-STAT3-dependent path-
way27. Tyrosine-phosphorylated STAT3 activates transcription of target genes, causing negative feedbacks on LEP 
signalling through the inhibition of LEPR phosphorylation. Likewise, the protein tyrosine phosphatase PTP1B 
interferes with LEP by dephosphorylating JAK2. However, our study does not show a significant modulation of 
PTP1B following hypoxia. Additional LEP-dependent pathways include JAK2-induced activation of the insulin 
receptor substrate/PI3K signalling and protein kinase c-Jun N-terminal kinase. In the heart, the LEP-associated 
PI3K pathway, along with ERK cascades, plays an important role in protecting cardiac cells from ischemia/rep-
erfusion injury28, 29. Moreover, the α and β isoforms of p38 MAPK, which are abundantly expressed in the heart, 
Figure 5. Angiocrine activity of APC-secreted LEP (a) LEPR silencing inhibited the proliferative effect of 
hypoxic APC-CM on HUVECs. *p < 0.05 and ***p < 0.001 vs. EGM2 #p < 0.05 vs. scramble. (b) LEPR silencing 
abolished the promotion of HUVEC network formation by hypoxic APC-CM. *p < 0.05 vs. EGM2 #p < 0.05 vs. 
scramble. (c) Blockade of LEP signalling increases the vascular resistance of HUVEC monolayers exposed to 
hypoxic APC-CM. ***p < 0.001 vs. control.
www.nature.com/scientificreports/
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may mediate the LEP ability to promote cardiomyocyte and vascular smooth muscle cell proliferation and hyper-
trophy16. Also, LEP-induced cardioprotection involves the stimulation of reparative vascularization. In vitro and 
in vivo evidence indicates that LEP-induced angiogenesis is dependent on stimulation of VEGF expression30 and 
activation of AKT and ERK31 and is synergistic with that of VEGF and FGF32. Of note, LEP has been implicated in 
the mobilization, adhesion to the site of vascular injury and vasculogenic activity of circulating angiogenic cells, 
via NOX2-mediated activation of metalloproteinase-9 and cross-talk of LEPR-SRC Kinase-Integrin αvβ533–35. 
LEP-induced increase in vascular permeability is essential for cell transmigration across the vasculature and also 
reportedly favors the release of paracrine factors, including LEP itself, in the circulation32. Our study indicates 
that the canonical STAT3 pathway plays a major role in the functional adaptation of APCs to hypoxia.
We have previously shown that APCs exert a paracrine angiogenic action through VEGF, ANG-1 and miR-
1326. The present study newly indicates that LEP is another key component of the APC angiogenic secretome. 
LEP reportedly induces VEGF expression in cancerous cells via canonical and non-canonical signalling path-
ways36, 37. However, in the present study, VEGF upregulation by hypoxia was not altered by LEP knockdown (our 
unpublished data), thus suggesting the prevalence of other stimulatory mechanisms different from the adipokine.
Our research provides important information regarding the putative interaction between LEP and miR-210. 
A study from Wu’s group showed that forced expression of miR-210 in HL-1 cardiomyocytes by transfection 
with a lentivirus carrying the miR-210 precursor stimulates the release of angiogenic factors, including Lep25. We 
found that miR-210 silencing does not affect the ability of hypoxic APCs to produce and release LEP. It should 
be pointed out that, in our study, miR-210 was upregulated by ~14 folds in APCs following induction of hypoxia, 
whereas, in Wu’s study, pre-miR-210 treatment increased the mature form of miR-210 by 124 fold25. A common 
limitation of the overexpression approach is that it is difficult to glean accurate biological insights when genes are 
expressed at extremely high, non-physiologic levels. Also, the targets of a specific microRNA may vary among 
different cells and species.
Clinical and commercial success of cell-based therapies rely on an in-depth understanding of the product’s 
critical quality attributes, namely the reproducible characteristics that ensure the product has the desired efficacy 
and safety profile. Therefore, we have established a rigorous production procedure to limit sources of variability 
Figure 6. Leptin secretion predicts capillarization outcome of APC therapy in a mouse model of limb ischemia. 
(a) Representative fluorescent microscopy images of capillary density in muscles injected with vehicle or 
APCs (bar = 50 μm). Capillaries are stained green with isolectin, myocytes stained red with α-SMA, nuclei are 
stained blue with DAPI. The LEP levels in conditioned media of hypoxic APC lines were assessed by ELISA. 
APCs producing higher levels of LEP induced more capillarization than those secreting lower levels of LEP. (b) 
Regression line showing the association between capillary density in injected skeletal muscles and level of LEP 
in conditioned media collected from hypoxic APCs (red circles). Vehicle group capillary density is shown as a 
light blue circle. (C&D) Vascular pericytes (c) and ECs (d) immunosorted from mouse adductor muscles 3 days 
after limb ischemia (Ischem) showed a significant increase in the expression of the mouse Lepr compared with 
contralateral normoperfused (Normop) muscles. ***p < 0.001 vs. normoperfused.
www.nature.com/scientificreports/
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associated with the APC manufacturing1. Nevertheless, biological variability represents an inevitable feature of 
cell therapy due to the nature of the products and clinical diversity of donors.
Importantly, re-analysing our previously published study10, we found that the abundance of APC-secreted 
LEP predicts the microvascular benefit, but not the perfusion outcome, of APC transplantation in mice with limb 
ischemia. We paid attention to avoid common limitations of retrospective studies, including selection bias at 
enrolment or differential loss to follow up. Nevertheless, our in vivo study represents a small scale project, whose 
aim was to provide initial proof of principle for the in vitro findings, thus supporting subsequent larger validation 
studies prior to guided therapeutic applications of APCs into human subjects. Furthermore, our search for an 
association between LEP and therapeutic outcomes was not intended to disclose a cause-effect relationship. We 
have previously shown that numerous paracrine factors contribute to the therapeutic action of human APCs5, 6, 9. 
The finding that ischemia induces the expression of the murine Lepr in resident vascular cells suggests favourable 
environmental conditions to the angiogenic action of LEP-expressing APCs.
Conclusions
This is the first study to report the functional importance of the LEP signalling pathway in human pericytes from 
the vascular adventitia. LEP is strongly upregulated by hypoxia, and this transcriptional modification confers 
pericytes with resistance to apoptosis and enhanced migratory and angiogenic activity (Fig. 7). These results have 
important implications for therapeutic revascularization of ischemic tissues and may also provide far-reaching 
interpretation of LEP-regulated processes involving perivascular cells, including vascular remodelling, athero-
sclerosis, and cancer.
Material and Methods
Ethics. Studies on cells from human subjects complied with the principles stated in the “Declaration of 
Helsinki” and were covered by ethical approvals (06/Q2001/197 and 14/WA/1005 for APC and BM-MSC studies, 
respectively, released by the National Institute for Social Care and Health Research – Research Ethics Service). 
All the subjects gave informed written consent for the experimental use of donated material. APCs were iso-
lated from vein leftovers of coronary artery bypass graft surgery patients, whose characteristics are reported in 
Supplementary Table I. In addition, BM-MSCs were isolated from bone surgical leftovers of patients (n = 3, age 
35–65 years), undergoing orthopaedic surgery for hip replacement at the Avon Orthopaedic Centre (Southmed 
Figure 7. Schematic representation of LEP signalling activated by hypoxia in human adventitial pericytes. 
An autocrine loop is activated through induced expression and secretion of LEP which binds to the LEPR on 
pericyte surface. The paracrine loop is mediated by secreted LEP inducing functional responses in other cells, 
like endothelial cells. The autocrine and paracrine loops result in functional adaptations to hypoxia. Arrows 
indicate enhanced or reduced function. Hypoxia activates miR-210, which in other cell types activates LEP 
production and PTP1B-mediated dephosphorylation of pJAK2. However, in human APCs, miR-210 is not 
responsible for modification of LEP secretion or signalling.
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Hospital, UK). Mononuclear fractions collected after Ficoll centrifugation were immuno-sorted using CD34/
CD45 microbeads (Miltenyi Biotec). BM-MSCs were used as control for LEP release since they are the current 
‘gold standard’ for cell therapy and regenerative medicine.
Experiments involving live animals were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals (the Institute of Laboratory Animal Resources, 1996) and with the approval from the British 
Home Office and the University of Bristol. Analysis of historical results followed the guidelines for the best prac-
tices for use of experimental data in laboratory animals38, 39.
Standard operating protocol for isolation and culture of human APCs. Cells were isolated and 
expanded from vein leftovers to obtain a total of 21 APC lines, using a standard operating protocol described in 
previous publications5, 10. Purity of the cell preparations was assessed by flow cytometry and immunocytochem-
istry. Experiments were performed at passage 7 (P7). We followed a randomization schedule for attribution of 
individual cell lines to different assays to eliminate the selection bias and avoid confounding from known and 
unknown factors.
Induction of hypoxia and collection of conditioned media. Confluent APCs were exposed to nor-
moxia (20% O2) or hypoxia (2% O2) for the time durations described in the result sections. FBS-free EGM-2 
media was used for the majority of studies, and it was also depleted of VEGF (VEGF/FBS-free EGM-2) in 
trans-endothelial electrical resistance assays. Morphological features of APCs were captured using a Nikon eclipse 
TS100 microscope, at 4x and 10x magnification. Cellular RNA and protein were collected using standard meth-
ods described below. CM were centrifuged at 12,000 g for 5 min to eliminate debris and floating cells and stored at 
−80 °C until assayed. Additionally, BM-MSCs were exposed to normoxia and hypoxia (20% and 2% O2, respec-
tively) for 48 h. FBS-free MEM media was used for the studies in BM-MSCs including collection of CM and RNA 
which were used thereafter in ELISA and qPCR studies
Flow cytometry analyses. APCs were stained for surface antigen expression using combinations of the fol-
lowing antibodies to confirm typical phenotype: CD105 (Life Technologies), CD90, CD73, PDGFRβ (Biolegend), 
CD44 (eBioscience), CD31 (BD Biosciences), CD34, and CD45 (Miltenyi)5, 10. Analysis was performed using 
a FACS Canto II flow cytometer and FACS Diva software (both BD Biosciences). BM-MSCs antigenic charac-
terization was also routinely performed by flow cytometry. Primers and antibodies are listed in Supplementary 
Tables VI and VII, respectively.
Immunocytochemistry. Cells were fixed with freshly prepared 4% PFA and probed with the follow-
ing antibodies – NG2 (1:100, Millipore), PDGFRβ (1:50, Santa Cruz), GATA4 (1:100), (all Abcam) followed 
by Alexafluor 488 anti-rabbit or anti-mouse secondary antibodies (Invitrogen). Always, isotype negative con-
trols were performed to ensure the immunofluorescence specificity. Cell nuclei were stained with 300 nM 
4′,6-diamidino-2-phenylindole dilactate (DAPI) (ThermoFisher Scientific). Images were acquired with a fluores-
cent microscope (Olympus BX40) at 40x magnification and merged using ImageJ software.
Gene arrays and bio-function analysis. Labelled cRNA was hybridised onto 4 × 44 k Agilent whole 
human genome microarrays overnight, washed and scanned, and the obtained 16 bit tiff images were analysed 
using Agilent Feature Extraction software. All steps were performed according to manufacturer’s instructions 
(Agilent Technologies).
Assessment of mRNA or microRNA expression by PCR. Total RNA was isolated using Trizol Reagent 
(Life Technologies) and miRNeasy mini kit (Qiagen) following the manufacturer’s instructions. RNA concentra-
tion and purity was assessed using a NanoDrop 2000 Spectrophotometer (ThermoFisher Scientific). Total RNA 
was reverse transcribed using a high-capacity RNA-to-cDNA kit for mRNA analysis, or using specific Taqman 
microRNA assay primers with a TaqMan® MicroRNA Reverse Transcription Kit for the assessment of microRNA 
expression (both Life Technologies). QPCR was performed using a Light Cycler 480 (Roche). Targeted genes are 
listed in Supplementary Table VI. Data were analysed using the 2−ΔΔCt method. The relative expression of each 
selected gene product was calculated by comparing the negative log of the Ct of the sample minus the Ct of the 
control gene (18 s or UBC) or microRNA (U6) in the same sample.
Gene silencing. Transient inhibition of the LEP or LEPR gene expression was performed using small interfer-
ing RNA (siRNA) molecules (ON-TARGETplus SMARTpool kit, GE Dharmacon). Control cells were exposed to 
scramble siRNA sequences (Silencer® Select Negative Control No. 2 siRNA, ThermoFisher Scientific). To investi-
gate the relationship between microRNA-210 and the LEP signalling pathway, we transfected human APCs with 
hsa-miR-210-3p anti-miR (AM10516). Reference APCs received anti-miR negative control (AM17010, both Life 
Tech). Transfection complexes were prepared using Opti-MEM media (ThermoFisher Scientific), Lipofectamine 
2000 (Invitrogen) and siRNA, anti-miR or control sequences following the manufacturer’s instructions. After 6 h, 
the lipocomplexes were removed, and fresh FBS or FBS/VEGF EGM2 was added as described above. Silencing 
efficiency was confirmed by qPCR and Western blot methods (see below).
Protein extraction. Cells were lysed in RIPA buffer containing phosphatase (1:50) and proteinase inhibitors 
(1:100, both Sigma). After incubation on ice, the whole APC lysates were centrifuged at 12,000 g for 10 min at 4 °C. 
Protein concentration was quantified using a BCA protein assay (ThermoFisher Scientific).
ELISA. LEP and VEGF levels in conditioned media and cellular lysates were quantified using Human Lep 
Duo Set ELISA (R&D Systems) following the manufacturer’s instructions. Protein lysates from APC lines from 
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miR210 inhibition experiments were tested by ELISA assay to investigate the regulation of pJAK2 Tyr 1007/1008 
(Ray Biotech, Cambridge Bioscience).
Western blotting. Protein samples were prepared in Laemmli loading buffer, incubated for 5–10 min at 
95 °C, resolved on 7.5% SDS-PAGE and transferred onto PVDF membranes (Immobilon-P PVDF Transfer 
Membrane 0.45 m, Millipore). Membranes were blocked using 5% BSA or 5% non-fat dried milk in TBS 0.05% 
Tween 20 (Sigma-Aldrich) for 1 h at 15–25 °C. Primary antibodies included pAKT Ser473, total AKT, pERK 1/2 
Thr 202/204, total ERK, PTP1B, total STAT3 (clone 124H6) (all 1:1000, Cell Signalling), and pSTAT3 Tyr705 
(clone D3A7, 1:2000, Cell Signalling), while -actin (1:5000, Clone AC15, Sigma-Aldrich) was used as loading 
control. Given the different sizes for AKT (60 KDa), STAT3 (80 KDa), ERK 1/2 (42–44 KDa), PTP1B (50 KDa) 
and actin (42 KDa), phosphorylated proteins were firstly assessed and the total protein was assessed thereaf-
ter. No more than two stripping procedures were performed in the same membrane (RestoreTM Plus Western 
Blot Stripping Buffer, Thermo Scientific). Anti-rabbit IgG or anti-mouse IgG were employed as secondary anti-
bodies (both 1:5000, GE Healthcare, Fisher Scientific). Membrane development was performed by an enhanced 
chemiluminescence-based detection method (ECL™ Prime Western Blotting Detection Reagent, GE Healthcare, 
Fisher Scientific) usually in a ChemiDoc MP system (Bio-Rad). Blot densitometry was analysed by using the 
Image J 5.1 software. In order to improve the clarity and conciseness of the blot data, they are displayed cropped 
in the text figures while original images are shown in Supplementary Material (Supplementary Figure V).
In vitro functional assays. Studies were conducted on human APCs exposed to exogenous recombinant 
human LEP (#398-LP-01M, R&D Systems) or inhibitors of the LEP system. Cell proliferation and apoptosis were 
measured using BrdU immunofluorescence (Roche) and CaspaseGlo 3/7 (Promega) assays, respectively, accord-
ing to the manufacturer’s instructions. Cell migration was assessed by the scratch assay as described previously10. 
The Matrigel network formation by HUVECs was performed as described10. Network formation was stimulated 
with the conditioned media of human APCs preliminarily exposed to normoxia or hypoxia. Images were taken 
under bright-field at 5x, and the number of branches, length, and thickness of the networks was measured using 
the ImageJ software. Real-time measurement of trans-endothelial electrical resistance by an automated electrical 
cell impedance sensing system (ECIS 1600R, Applied Biophysics) was employed to determine the effect of human 
APCs conditioned media on endothelial permeability. Briefly, HUVECs were seeded into 8-well arrays (Ibidi), 
at a density of 100,000 cells/well, and incubated for 24 h in EGM2 media. After 30 min stabilization, the HUVEC 
media was replaced with either conditioned media from human APCs preliminarily transfected with leptin 
silencing sequences or scramble control sequences. Alternatively, the LEP signalling was blocked in HUVECs by 
LEPR siRNA silencing and the above media added. Resistance was measured every 15 sec for 2 h.
In vivo experiments. We performed a retrospective analysis of LEP data from our recent published study, 
investigating the effect of five human APC lines in C57BL/6 mice with unilateral limb ischemia10. Unilateral 
limb ischemia was performed by ligation and electrical cauterization of the left femoral artery. This was followed 
by injection of human APCs (8 × 104 cells in 30 μL, P7) or PBS (vehicle) into 3 different points of the operated 
adductor muscle (n = 7 animals per group). In this re-assessment of the study, we determined if the levels of LEP 
in CM of human APCs allow predicting the cell capacity to stimulate angiogenesis in ischemic muscles. Details of 
the methodology to assess capillary angiogenesis is provided in ref. 10.
Isolation of endothelial cells and pericytes from mouse ischemic limb muscles. Adductor mus-
cles from mice at 3 days post-ischemia induction were rinsed and digested with collagenase II (Worthington) plus 
DNase I (Sigma) using gentleMACS™ Dissociator, following the manufacture’s protocol. Next, pericytes and ECs 
were immunomagnetically sorted using NG2 and CD31 antibodies, respectively (Miltenyi Biotech). Purity of cell 
preparations was analyzed by flow cytometry.
Statistical Analysis. Analyses and graph drawings were performed using the SPSS 19.0 for Windows (SPSS, 
Inc., Chicago, IL, USA) and GraphPrism 6.0 statistical packages. Continuous variables were tested for normal 
distribution by Kolmogorov–Smirnov Z test and shown as mean ± standard error of the mean (SEM) or median 
(IQR). Categorical variables and flow cytometry events are presented as percentages. Continuous variables with 
normal distribution were compared using the t-Student (two group comparison) or one-way analysis of variance 
(ANOVA for multiple group comparisons), as appropriate. In specific studies, two-way ANOVA was applied to 
compare the mean differences between groups that have been split into two independent variables and verify if 
there was an interaction between the two independent variables on the dependent variable. Homoscedasticity was 
assessed with the Levene test, and posthoc analysis of ANOVA included Tuckey or Bonferroni and T3 Dunnet, 
as appropriate. Non-parametric tests including the Mann–Whitney U test or the Kruskall-Wallis test were used 
for samples not normally distributed. Correlation between variables and microvascular endpoints was calculated 
by regression analysis. Processing and statistical analysis of gene arrays were done in R/Bioconductor5 and gene 
set enrichment was performed using ClueGO 6 and GATHER. Statistical significance was accepted at p < 0.05.
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